Datapoint: Dupixent Scores First-in-Class EoE Nod

Sanofi and Regeneron’s Dupixent last week became the first drug approved to treat eosinophilic esophagitis (EoE), a rare, progressive disease that causes severe inflammation of the esophagus. The FDA’s decision came more than two months before Dupixent’s original priority review date. The interleukin inhibitor was first approved in 2017, as a treatment for atopic dermatitis. For the treatment of atopic dermatitis, Dupixent holds covered or better status for 89% of all insured lives under the pharmacy benefit. 39% of insured lives have preferred access to Dupixent, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 5/23/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 24

Datapoint: Priority Health to Acquire Indiana Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today